Koninklijke Philips (NYSE:PHG) Lifted to "Neutral" at UBS Group

UBS Group upgraded shares of Koninklijke Philips (NYSE:PHG - Free Report) from a sell rating to a neutral rating in a research note published on Tuesday morning, Marketbeat.com reports.

A number of other equities research analysts have also commented on the stock. StockNews.com raised shares of Koninklijke Philips from a buy rating to a strong-buy rating in a report on Thursday, February 8th. BNP Paribas lowered shares of Koninklijke Philips from an outperform rating to an underperform rating in a research note on Wednesday, February 7th. Finally, JPMorgan Chase & Co. raised shares of Koninklijke Philips from an underweight rating to a neutral rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of Hold and a consensus price target of $19.00.

Koninklijke Philips Price Performance

Shares of PHG stock traded down $0.16 during mid-day trading on Tuesday, reaching $26.55. The company's stock had a trading volume of 3,826,482 shares, compared to its average volume of 1,164,019. Koninklijke Philips has a 1-year low of $17.75 and a 1-year high of $29.44. The company has a market cap of $24.66 billion, a P/E ratio of -46.58, a PEG ratio of 1.09 and a beta of 0.88. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.78 and a current ratio of 1.20. The firm's 50-day moving average is $20.56 and its two-hundred day moving average is $20.99.

Koninklijke Philips (NYSE:PHG - Get Free Report) last posted its earnings results on Monday, January 29th. The technology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Koninklijke Philips had a negative net margin of 2.53% and a positive return on equity of 14.17%. The business had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.47 billion. On average, research analysts predict that Koninklijke Philips will post 1.53 earnings per share for the current year.

Institutional Trading of Koninklijke Philips

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Brandywine Global Investment Management LLC bought a new position in shares of Koninklijke Philips in the third quarter valued at $36,544,000. Russell Investments Group Ltd. boosted its position in Koninklijke Philips by 85.6% during the fourth quarter. Russell Investments Group Ltd. now owns 1,033,823 shares of the technology company's stock worth $24,119,000 after purchasing an additional 476,907 shares during the period. Brandes Investment Partners LP boosted its position in Koninklijke Philips by 48.7% during the fourth quarter. Brandes Investment Partners LP now owns 1,285,935 shares of the technology company's stock worth $30,001,000 after purchasing an additional 421,055 shares during the period. OLD Mission Capital LLC boosted its position in Koninklijke Philips by 434.9% during the fourth quarter. OLD Mission Capital LLC now owns 434,282 shares of the technology company's stock worth $10,132,000 after purchasing an additional 353,096 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in Koninklijke Philips by 29.4% during the third quarter. Envestnet Asset Management Inc. now owns 1,447,942 shares of the technology company's stock worth $28,872,000 after purchasing an additional 328,922 shares during the period. 13.67% of the stock is currently owned by institutional investors and hedge funds.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.